Hinge Region Cys-to-Ser Mutation Enables Homogeneous DAR6 Anti-c-Met Biparatopic ADCs with Tolerable O-Glycosylation

Antibody Therapeutics · Published 2026-07-30 · DOI 10.1093/abt/tbag040

Free full text

Authors (13)

Deyong Song, Zhenduo Shen, Xiaolin Zhu, Haifeng Zhao, Yingdi Wang, Junmei Zhang, Rui Li, Hongguang Xu, Zengjin Cheng, Xiaoju Ma, Haixia Lin, Changlin Dou, Min Xiao

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Song, D., Shen, Z., Zhu, X., et al. (2026). Hinge Region Cys-to-Ser Mutation Enables Homogeneous DAR6 Anti-c-Met Biparatopic ADCs with Tolerable O-Glycosylation. Antibody Therapeutics. https://doi.org/10.1093/abt/tbag040

Related articles

• The evolving landscape of enzymatic technologies for precision synthesis of antibody–drug conjugates · Antibody Therapeutics · 2026 · Same journal
• Beyond Affinity: AI-Supported Developability Assessment and Multi-Objective Optimization in Antibody Development · Antibody Therapeutics · 2026 · Same journal
• Mass photometry reveals stoichiometry and binding dynamics of bispecific tetravalent anti-VEGF-PD-1 antibody ivonescimab · Antibody Therapeutics · 2026 · Same journal
• Anti-ANGPTL3 antibody and IL-22 fusion protein mitigate nephrotic syndrome via mitochondrial protection, anti-apoptosis, and autophagy suppression · Antibody Therapeutics · 2026 · Same journal
• Delivery devices and container closure systems for co-formulated and co-administered biologics · Antibody Therapeutics · 2026 · Same journal
• Integrative and Emerging Models in Antibody Research: A Comprehensive Review · Antibody Therapeutics · 2025 · Same journal
• Why antibody isotype matters for immunotherapy · Antibody Therapeutics · 2026 · Same journal
• Design and Therapeutic Rationale of Antibody-Peptide Conjugates: Insights from Maridebart Cafraglutide (AMG133) and Emerging Applications · Antibody Therapeutics · 2025 · Same journal
• Fundamental properties and principal areas of focus in antibody–drug conjugates formulation development · Antibody Therapeutics · 2025 · Same journal
• Analysis of the use of monoclonal antibodies in the treatment of Crohn’s disease · Antibody Therapeutics · 2026 · Same journal